Terguride--a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine.

Terguride, the C9-10 dihydrogenated derivative of lisuride, is a new drug which inhibits pituitary prolactin (PRL) secretion. It has mixed dopaminergic-antidopaminergic and alpha 2-antiadrenergic activity, and has proved useful in the clinical management of hyperprolactinemia. However, no trial comp...

書誌詳細
主要な著者:	Ciccarelli, E, Touzel, R, Besser, M, Grossman, A
フォーマット:	Journal article
言語:	English
出版事項:	1988

類似資料

The rapid diagnosis of sensitivity or resistance to dopamine agonists with depot bromocriptine.
著者:: Grossman, A, 等
出版事項: (1987)

Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: a double-blind study.
著者:: Verhelst, J, 等
出版事項: (1991)

Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine
著者:: Marianne F. Clausen, 等
出版事項: (2021-12-01)

DEPOT BROMOCRIPTINE IN THE TREATMENT OF PROLACTINOMAS AND ACROMEGALY
著者:: Grossman, A, 等
出版事項: (1985)

Depot-bromocriptine treatment for prolactinomas and acromegaly.
著者:: Grossman, A, 等
出版事項: (1986)

Long-term treatment with a new repeatable injectable form of bromocriptine, Parlodel LAR, in patients with tumorous hyperprolactinemia.
著者:: Ciccarelli, E, 等
出版事項: (1989)

Glucose Intolerance Induced by Oligemic Brain Hypoxia: The Effect of Terguride
著者:: Věroslav Golda, 等
出版事項: (1997-01-01)

Bromocriptine, a Dopamine (D2 ) Receptor Agonist, Used Alone and in Combination with Glipizide in Sub–Therapeutic Doses to Ameliorate Hyperglycaemia
著者:: Harish Kumar V.S., 等
出版事項: (2013-09-01)

Dopaminergic agonist bromocriptin in treatment of diabetes mellitus type 2
著者:: O A Gerasimenko, 等
出版事項: (2011-12-01)

Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes
著者:: G. Tavares, 等
出版事項: (2021-09-01)

Oral prednisolone supplement abolishes the acute adverse effects following initiation of depot bromocriptine therapy.
著者:: Jenkins, P, 等
出版事項: (1996)

Two new dopamine agonists that are long acting in vivo but short acting in vitro.
著者:: Grossman, A, 等
出版事項: (1980)

The effect of dopamine agonist therapy on large functionless pituitary tumours.
著者:: Grossman, A, 等
出版事項: (1985)

The Dark Side of Dopamine Agonist Therapy in Prolactinoma Management
著者:: Sonia Ananthakrishnan, MD
出版事項: (2017-01-01)

A bromocriptine-responsive corticotroph adenoma secreting alpha-MSH in a patient with Cushing's disease.
著者:: Hale, A, 等
出版事項: (1988)

Hyperprolactinemia in Obese as Well as in Lean Females of Koletsky Rats: Effect of Long Lasting Terguride Treatment
著者:: Věroslav Golda, 等
出版事項: (1998-01-01)

PROLACTINOMA IN A PREPUBERTAL CHILD - RESPONSE TO SURGERY, RADIOTHERAPY AND DOPAMINE AGONIST THERAPY
著者:: Sinn, D, 等
出版事項: (1985)

Cabergoline or bromocriptine for prolactinoma?
著者:: Nicolás Triantafilo, 等
出版事項: (2016-09-01)

A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea
著者:: Ismail, I.S., 等
出版事項: (1994)

The side effects of dopamine receptor agonist drugs in Chinese prolactinoma patients: a cross sectional study
著者:: Xiaoan Ke, 等
出版事項: (2022-04-01)

Central Hyperthermia Treated with Bromocriptine
著者:: P. Natteru, 等
出版事項: (2017-01-01)

Bromocriptine in the Management of Central Hyperthermia
著者:: Krishnaprasad Narayanankutty, 等
出版事項: (2024-08-01)

Repurposing of Bromocriptine for Cancer Therapy
著者:: Ean-Jeong Seo, 等
出版事項: (2018-10-01)

A comparison between Bromocriptine and Selegiline in treatment of Parkinsons disease
著者:: A Ahmadi Ahangar, 等
出版事項: (2002-07-01)

Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
著者:: Michael A Via, 等
出版事項: (2010-03-01)

Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
著者:: Via MA
出版事項: (2010-03-01)

Impact of behavioral side effects on the management of Parkinson patients treated with dopamine agonists
著者:: Mohammad Edrees Mohammad, 等
出版事項: (2021-01-01)

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
著者:: Xiaoshuang Liu, 等
出版事項: (2019-01-01)

Effect of Long Lasting Terguride Treatment on Mutual Relationship Between Glycide and Lipid Parameters in SHR/N-cp Koletsky Rats
著者:: Věroslav Golda, 等
出版事項: (1998-01-01)

Bromocriptine for type 2 diabetes mellitus
著者:: Ooi, Cheow Peng, 等
出版事項: (2013)

Bromocriptine in type 2 diabetes mellitus
著者:: C Shivaprasad, 等
出版事項: (2011-01-01)

The diagnosis and medical management of advanced neuroendocrine tumors.
著者:: Kaltsas, G, 等
出版事項: (2004)

Could Dopamine Agonists Aid in Drug Development for Anorexia Nervosa?
著者:: Guido eFrank
出版事項: (2014-11-01)

Two new dopamine agonists that are long acting in vivo but short acting in vitro
著者:: Grossman, A, 等
出版事項: (1980)

The potential role of D(2) dopamine receptors as a target in the management of neuroendocrine tumors.
著者:: Ribeiro-Oliveira, A, 等
出版事項: (2008)

Dopamine Agonists and Pathologic Behaviors
著者:: Brendan J. Kelley, 等
出版事項: (2012-01-01)

Case report: Open bite as an extrapyramidal side effect with aripiprazole, a dopamine partial agonist
著者:: Satoko Sumi, 等
出版事項: (2022-09-01)

Bromocriptine use is associated with decreased smoking rates.
著者:: Murphy, M, 等
出版事項: (2002)

A peripartum cardiomyopathy case treated with bromocriptine
著者:: Dilek Yeşilbursa, 等
出版事項: (2021-03-01)

Bromocriptine and insulin sensitivity in lean and obese subjects
著者:: L Bahler, 等
出版事項: (2016-11-01)